Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INOvation-1: Inhaled Nitric Oxide in Symptomatic Pulmonary Arterial Hypertension
2015-005223-90Phase 3Terminated
- Sponsor
- Bellerophon Therapeutics
- Start
- Apr 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Pulsed inhaled nitric oxide (INOpulse) with Placebo (sham INOpulse delivery) (2 arms). Primary endpoint: Primary endpoints (Part 1 blinded treatment period). Started Apr 2016; status: terminated.
02
Drugs
nitric oxide
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2015-005223-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005223-90.